Fresh Leukopaks for Cell Therapy

Supported by a broad, diverse, and well-characterized donor network, rapid delivery, and a robust supply chain, our fresh leukopaks provide the reliable starting material needed for cell therapy development.

Product Overview

Fresh leukopaks are a primary source of immune cells widely used as starting material for cell therapy research, process development, and manufacturing. Collected via leukapheresis, they provide a high yield of viable mononuclear cells, including T cells, NK cells, and other relevant immune subsets.


 

Our fresh leukopaks are sourced from a large and diverse donor network and produced under standardized collection protocols to ensure consistency, traceability, and documentation. Each leukopak is supported by comprehensive donor qualification and safety testing in alignment with applicable regulatory and ethical requirements.


 

With established collection capabilities across Europe and the US, our fresh leukopaks are shipped within 24 hours post collection under strict quality control and temperature regulated conditions, ensuring cellular integrity, high viability, and reliable, scalable access to consistent immune cell material, supporting a smooth transition from early stage research through clinical development and into commercial manufacturing.

Uses of leukopaks

Isolation of peripheral blood mononuclear cells (PBMCs) populations such as T cells, NK cells and monocytes

Activation, genetic engineering, and expansion of immune cells

Process development and optimization

Donor selection and cell banking for allogenic platforms

Key Features

Donor Sourcing & Characterization

  • Grifols sources leukopaks through a broad and well‑established donor network, supported by multiple collection sites in Europe (Germany) and the US, enabling access to diverse immune cell compositions and flexible sourcing options aligned with cell therapy development needs.
  • Donors are well characterized, allowing selection based on defined criteria such as age, sex, HLA type, CMV status, blood type, and immunophenotyping.
  • Grifols enables donor continuity through recallable donors, allowing repeat collections from the same donor. In addition, established back‑up donor scheduling for each donation ensures reliable, on‑time availability and delivery for each collection.
  • All donors undergo stringent screening and continuous monitoring, as leukopak donors are sourced from Grifols established plasma donor network, which provides extensive historical data, resulting in a higher level of safety, consistency, and traceability.

Leukopak Core Characteristics

  • Adaptable collection options including flexible collection volumes and additional optional plasma volumes.
  • High concentrations of key immune cell subsets, such as defined CD4/CD8 ratios or monocyte content, together with consistently high cell viability.1,2
  • Robust traceability is maintained across the entire product lifecycle, supporting a smooth transition from research use only (RUO) to good manufacturing practice (GMP) formats and ensuring consistency in quality and scalability.
  • Additional processing options, including irradiation to inhibit cellular proliferative capacity.

 

1. Gómez I, Schaffer JM, Winterstein K, et al. Optimizing cell sourcing for cell therapy by reducing donor variability with recallable leukopak donors for enhanced standardization. Cytoherapy. 2025;27(5 Suppl):S141

2. Gómez-Gràcia I, Gonnermann D, Paschold L, et al. Donor demographics and leukopak consistency: yield and composition as operational benchmarks for cell-therapy starting materials. Curr Res Transl Med. 2026;74(3):103591
 

Multiple Formats Aligned with Customer Needs

  • Full Leukopak: Provides >10 billion total cells from a single donor collection, enabling high‑yield cell sourcing suitable for large‑scale cell therapy development and manufacturing workflows.
  • Half Leukopak: Contains >5 billion total cells, offering a more flexible format for early‑stage studies, parallel experiments, and process optimization while maintaining consistent cell quality.
  • Split Leukopak: Derived from a single donor, single donation, and aseptically divided into 2 bags. Each unit retains the original cellular profile for consistent comparative and validation studies.

Quality Grade

Fresh leukopaks are available in different quality grades to support cell therapy programs at various stages of development.

Each grade is defined by specific quality controls, testing scope, and documentation packages aligned with its intended use.

 

RUO (Research Use Only)

Designed to support early-stage research, assay development, and process optimization. This grade enables flexibility and efficiency during exploratory development while maintaining high safety and quality standards.

Key characteristics:

  • Collected under control conditions from qualified donors
  • Core quality control testing performed
  • Viral marker testing conducted on each donation
  • Complete blood count and cell concentration analysis included
  • Documentation package suitable for research and non-clinical applications

GMP Aligned

Intended to support regulated clinical development and manufacturing readiness. This grade provides the additional level of control, testing, and documentation required for cell therapy programs progressing toward clinical and regulated environments.

Key characteristics:

  • Donor screening and collection processes aligned with GMP expectations
  • Expanded quality control and safety testing
  • Enhanced documentation and traceability to support regulatory submissions
  • Designed to support progression toward clinical development and commercial manufacturing

Regulatory & Documentation Support

Robust documentation and analytical data are provided to support donor characterization, traceability, and quality assessment in cell therapy workflows.

  • Certificate of analysis (CoA)
  • Quality control (QC)
  • Viral marker testing performed on every donation
  • Complete blood count and cell concentration analysis included
  • Optional immunophenotyping: CD3, CD4, CD8, CD14, CD19, CD56 (on demand)

Product Formats

Fresh leukopaks are available in multiple formats to support diverse cell therapy development needs.

Product

Provides >10 billion total cells collected from a single donor.
Best suited for: large-scale cell therapy development and manufacturing workflows.

Key features
  • Dual sourcing from compliant centers in the US and Europe 
  • High cell concentration, providing high yield of mononuclear cells 
  • Comprehensive donor profile, including detailed blood profile and donor specifications
  • Available in RUO and GMP formats

Provides >5 billion total cells from a single donor collection. Best suited for: early-stage protocols, new methods and parallel development.

Key features
  • Reduced-volume format
  • Full donor characterization retained for regulatory and quality requirements.
  • Available in RUO and GMP formats

From a single donor, aseptically divided into two bags. 
Best suited for: comparative, validation, technology transfer and stability studies.

Key features
  • Identical cellular composition across splits
  • Available in RUO
Product Key features

Full Leukopak 

Provides >10 billion total cells collected from a single donor.
Best suited for: large-scale cell therapy development and manufacturing workflows.

  • Dual sourcing from compliant centers in the US and Europe 
  • High cell concentration, providing high yield of mononuclear cells 
  • Comprehensive donor profile, including detailed blood profile and donor specifications
  • Available in RUO and GMP formats

Half Leukopak

Provides >5 billion total cells from a single donor collection. Best suited for: early-stage protocols, new methods and parallel development.

  • Reduced-volume format
  • Full donor characterization retained for regulatory and quality requirements.
  • Available in RUO and GMP formats

Split Leukopak

From a single donor, aseptically divided into two bags. 
Best suited for: comparative, validation, technology transfer and stability studies.

  • Identical cellular composition across splits
  • Available in RUO

Available for Order

Configure fresh leukopaks online according to your donor and product requirements and receive a personalized quotation.

Cell Therapy Applications

CAR‑T Cell Therapies

Leukopaks provide high‑yield, viable T cells that serve as the starting material for CAR‑T engineering, enabling efficient cell isolation, genetic modification, and expansion across research and manufacturing workflows.

TCR‑Engineered Cell Therapies

A reliable source of functional T lymphocytes used in TCR‑based programs, supporting receptor engineering and downstream process development for targeted cell therapies.

NK‑Cell Immunotherapies

Supply NK cells suitable for activation and expansion in autologous and allogeneic NK‑based therapeutic platforms, supporting next‑generation immune‑cell therapies.

Allogeneic (Off the Shelf) Immune Cell Therapies

Single‑donor leukopaks enable donor selection, cell banking, and standardized immune‑cell sourcing, supporting scalable and consistent allogeneic cell therapy development.

Why Grifols Bio Supplies

Pharma‑to‑Pharma

Backed by decades of plasma-derived product and biopharmaceutical manufacturing experience, Grifols Bio Supplies applies pharma-grade manufacturing discipline, controlled processes, and rigorous documentation to deliver cell therapy developers a high-quality starting material and operational support.

Worldwide Donor Network

Access to a large, diverse, and well-characterized donor network supported by multiple collection sites in the US and Europe, enabling broader immune-cell sourcing options and robust cell therapy process development.

Quality & Safety

Our leukopak donors are sourced from Grifols’ established plasma donor network, enabling stringent donor screening, continuous monitoring, and access in many cases to extensive donor historical data. Combined with controlled processing and comprehensive testing, this provides an additional layer of safety and traceability.

High-Yield Immune Cell Starting Material

Leukapheresis-derived leukopaks provide large quantities of viable mononuclear cells enabling efficient downstream processing and reducing the need for multiple collections.

Reliable Global Supply

A global infrastructure designed to support scalable, long‑term supply for cell therapy programs.

Regulatory & Documentation Support

Comprehensive documentation aligned with donor characterization, traceability, and regulatory expectations, supporting cell therapy developers as they advance toward GMP-ready processes.

Product Resources

Explore additional technical resources and product information to support your leukopak sourcing and cell therapy development activities.

Product Brochure

Download

Cell Therapy Brochure

Download

Cell Therapy Infographic

Download

Related Cell Therapy Products

To support cell therapy manufacturing, complementary products are available to help protect and stabilize cell quality during critical processing steps, from upstream handling through downstream formulation.

Cryopreserved leukopaks

A leukapheresis-derived immune cell source preserved through controlled freezing to maintain viability and functionality after thawing, enabling flexible use over time and supporting consistent, standardized workflows in cell therapy development and manufacturing.

Human serum albumin

A versatile plasma-derived protein with strong stabilizing properties that help maintain cell viability, prevent aggregation, and improve cell retention during cell handling and processing, including culture, washing, and cryopreservation.

Human male AB serum

A widely used cell culture supplement that offers a balanced mix of growth factors, hormones and attachment agents minimizing immunological risk and enhancing biological compatibility supporting improved cell viability and expansion.

Have questions before requesting a quote?

Contact our team for product information, technical guidance, or assistance selecting the right solution for your application.

FAQs

A leukopak is a bloodderived product highly enriched in mononuclear leukocytes, including lymphocytes and monocytes. They are widely used in cell therapy research and manufacturing because they provide a large, concentrated source of cells for downstream processes such as cell expansion, activation, or genetic modification.

We use the Terumo Spectra Optia® apheresis system, an industry standard platform for high quality mononuclear cell collections.

Fresh leukopaks are delivered within 24 hours of collection.
We ensure reliable delivery by maintaining backup donors to avoid supply interruptions.

Customers can request specific donor attributes, such as age range, sex, race, CMV status, HLA typing, and other relevant criteria depending on their project needs and region collection (US or Europe).

We ship fresh leukopaks across the United States and Europe, including the United Kingdom.

You can order fresh leukopaks in two ways:
1. Request a Quote (RFQ) 
Use our RFQ tool to configure fresh leukopaks based on your donor and product requirements and submit your request for a personalized quotation.
2. Contact Us 
Complete our Contact Us form to discuss your project with our team, and we'll help identify the best leukopak solution for your needs.
For the fastest experience, we recommend using the RFQ tool, as it allows our team to receive your requirements upfront and respond with a tailored quote more efficiently.